Drugs / A/H2N3c
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05875961 | Jun 2023 → Nov 2024 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/H2N3c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05875961 ↗ |
| Modality | Vaccine | “H2N3 influenza vaccine” NCT05875961 ↗ |
| Route | Intramuscular | “Two intramuscular injections (3 weeks apart)” NCT05875961 ↗ |